<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01938144</url>
  </required_header>
  <id_info>
    <org_study_id>B3971002</org_study_id>
    <secondary_id>U1111-1147-8736</secondary_id>
    <nct_id>NCT01938144</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of Two Ibuprofen Combination Products for the Treatment of the Common Cold and Flu in Latin America</brief_title>
  <official_title>Three-day Clinical Evaluation Of The Efficacy And Safety Of Two Ibuprofen Combination Products For The Symptomatic Treatment Of The Common Cold And Flu: A Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, prospective, randomized, double-blind, triple-dummy, parallel group,
      comparative, study designed to evaluate the efficacy of Ibuprofen (IBU) 200 mg/ Phenylephrine
      (PE) 10 mg and IBU 200 mg/ PE 10 mg/ Chlorpheniramine (CHLOR) 4 mg on the relief of symptoms
      of the common cold and flu. The reference product that the active treatments will be compared
      to is paracetamol (PARA) 500 mg.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the sum of 6 of the most common cold and flu symptoms (runny nose, plugged nose, sneezing, sore throat, scratchy throat, and head congestion), averaged over the treatment period assessed using the Wisconsin Upper Respiratory</measure>
    <time_frame>2 Days</time_frame>
    <description>The severity of cold/flu symptoms will be determined by the subject's response to the Wisconsin Upper Respiratory Symptom Survey, which includes questions related to the signs and symptoms of cold and flu, as well as Quality of Life Measures.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptom Survey - 21</measure>
    <time_frame>2 Days</time_frame>
    <description>The severity of cold/flu symptoms will be determined by the subject's response to the Wisconsin Upper Respiratory Symptom Survey, which includes questions related to the signs and symptoms of cold and flu, as well as Quality of Life Measures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the sum of all 10 common cold and flu symptoms, averaged over the treatment period.</measure>
    <time_frame>2 Days</time_frame>
    <description>The severity of cold/flu symptoms will be determined by the subject's response to the Wisconsin Upper Respiratory Symptom Survey, which includes questions related to the signs and symptoms of cold and flu, as well as Quality of Life Measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the sum of 6 of the most common symptoms at each assessment (PM day 1, AM and PM day 2)</measure>
    <time_frame>2 Days</time_frame>
    <description>The severity of cold/flu symptoms will be determined by the subject's response to the Wisconsin Upper Respiratory Symptom Survey, which includes questions related to the signs and symptoms of cold and flu, as well as Quality of Life Measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom relief since taking the first dose</measure>
    <time_frame>1 hours</time_frame>
    <description>One Hour Assessment of Relief question following the first dose</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Common Cold</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IBU 200 mg/ PE 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IBU 200 mg/ PE 10 mg/CHLOR 4 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acetaminophen 500 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Advil Congestion Relief</intervention_name>
    <description>Orally adminstered, 200 mg Ibuprofen/10 mg Phenylephrine tablet, 4x/day, up to 8 doses.</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Advil Allergy and Congestion Relief</intervention_name>
    <description>Orally adminstered, 200 mg Ibuprofen/10 mg Phenylephrine/4 mg Chlorpheniramine tablet, 4x/day, up to 8 doses.</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>Acetaminophen 500 mg, 4x/day, up to 8 doses.</description>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male and female subjects who are 18 years old or older at the time of screening.

        Subjects who are willing and able to comply with scheduled visits, treatment plan,
        laboratory tests, and other study procedures.

        Subjects must present with a score of 5 of higher for at least 2 of the following 6
        symptoms: runny nose, plugged nose, sneezing, sore throat, scratchy throat, or head
        congestion on the WURSS-21 assessment, within 36 hours of onset of symptoms.

        Exclusion Criteria:

        Anyone with a history of chronic allergic rhinitis or asthma at the time of the screening
        visit, or with history of chronic recurrent airway disease, infections, or frequent
        complications of colds (otitis media, sinusitis, or bronchitis)

        Subjects taking any prescription or non-prescription drug, within the last 7 days prior to
        the screening, with which the administration of IBU, PE, CHLOR, or APAP is contraindicated,
        may increase the risk associated with study participation, or may interfere with the
        interpretation of study results, in the judgment of the Investigator.

        Subjects currently taking a monoamine oxidase (MAO) inhibitor, or has taken an MAO
        inhibitor within 2 months of screening.

        Subjects currently taking a serotonin-selective reuptake inhibitor (SSRI), tricyclic
        antidepressant (TCA), barbiturate, or any other neuroleptic, or has taken an SSRI, TCA,
        barbiturate, or any other neuroleptic within 14 days of screening.

        Subjects with a hypersensitivity to IBU, PE, or CHLOR or APAP.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3971002&amp;StudyName=Evaluation%20of%20the%20Efficacy%20and%20Safety%20of%20Two%20Ibuprofen%20Combination%20Products%20for%20the%20Treatment%20of%20the%20Common%20Cold%20and%20Flu%20in%20Latin%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2013</study_first_submitted>
  <study_first_submitted_qc>September 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2013</study_first_posted>
  <last_update_submitted>October 13, 2015</last_update_submitted>
  <last_update_submitted_qc>October 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Common cold</keyword>
  <keyword>efficacy</keyword>
  <keyword>symptoms</keyword>
  <keyword>Wisconsin Upper Respiratory Symptom Survey - 21</keyword>
  <keyword>ibuprofen</keyword>
  <keyword>phenylephrine</keyword>
  <keyword>pseudoephedrine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Common Cold</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

